Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADAP Adaptimmune Therapeutics	$0.29 -2.5%	$0.30	$0.20 ▼ $1.48	$75.27M	2.86	1.76 million shs	644,935 shs
ATAI Atai Life Sciences	$1.39 -0.7%	$1.42	$1.03 ▼ $2.57	$277.72M	1.22	1.52 million shs	1.08 million shs
AURA Aura Biosciences	$5.23 -9.8%	$6.12	$4.84 ▼ $12.38	$262.68M	0.43	205,960 shs	227,320 shs
FULC Fulcrum Therapeutics	$5.37 -0.7%	$3.38	$2.32 ▼ $10.13	$289.87M	2.29	973,552 shs	537,283 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADAP Adaptimmune Therapeutics	-2.47%	+2.34%	+25.42%	-52.81%	-74.33%
ATAI Atai Life Sciences	-0.36%	-7.33%	+6.92%	-36.24%	-30.85%
AURA Aura Biosciences	-9.83%	-14.96%	-2.43%	-32.95%	-29.23%
FULC Fulcrum Therapeutics	-0.74%	-4.45%	+86.46%	+45.53%	-29.25%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADAP Adaptimmune Therapeutics	3.2143 of 5 stars	4.3	5.0	2.8	0.8	0.0
ATAI Atai Life Sciences	2.9914 of 5 stars	3.5	1.0	3.3	3.3	1.3
AURA Aura Biosciences	2.2998 of 5 stars	3.6	2.0	2.9	2.5	0.0
FULC Fulcrum Therapeutics	1.9427 of 5 stars	3.1	2.0	3.2	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADAP Adaptimmune Therapeutics	2.67	Moderate Buy	$1.83	525.43% Upside
ATAI Atai Life Sciences	3.00	Buy	$10.50	655.40% Upside
AURA Aura Biosciences	3.25	Buy	$22.75	334.99% Upside
FULC Fulcrum Therapeutics	2.11	Hold	$8.63	60.61% Upside

Current Analyst Ratings Breakdown

Latest ADAP, FULC, AURA, and ATAI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/11/2025	ADAP Adaptimmune Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
4/1/2025	ADAP Adaptimmune Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$3.50 ➝ $3.00
3/26/2025	AURA Aura Biosciences	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$19.00
3/26/2025	AURA Aura Biosciences	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
3/26/2025	ADAP Adaptimmune Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$3.00 ➝ $1.75
3/25/2025	AURA Aura Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$25.00
3/24/2025	AURA Aura Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00 ➝ $22.00
3/21/2025	ADAP Adaptimmune Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$2.00 ➝ $1.50
3/21/2025	ADAP Adaptimmune Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$3.15 ➝ $1.40
3/19/2025	ATAI Atai Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
2/26/2025	FULC Fulcrum Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$4.00 ➝ $4.00

(Data available from 5/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADAP Adaptimmune Therapeutics	$178.03M	0.42	N/A	N/A	$0.17 per share	1.72
ATAI Atai Life Sciences	$308K	901.67	N/A	N/A	$1.47 per share	0.95
AURA Aura Biosciences	N/A	N/A	N/A	N/A	$4.58 per share	N/A
FULC Fulcrum Therapeutics	$80M	3.62	N/A	N/A	$3.80 per share	1.41

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADAP Adaptimmune Therapeutics	-$113.87M	-$0.27	N/A	N/A	N/A	-25.43%	-74.15%	-15.09%	5/13/2025 (Estimated)
ATAI Atai Life Sciences	-$40.22M	-$0.93	N/A	N/A	N/A	N/A	-65.75%	-52.71%	5/13/2025 (Estimated)
AURA Aura Biosciences	-$76.41M	-$1.75	N/A	N/A	N/A	N/A	-41.57%	-36.43%	N/A
FULC Fulcrum Therapeutics	-$97.33M	-$0.07	N/A	N/A	N/A	N/A	-7.31%	-6.74%	5/12/2025 (Estimated)

Latest ADAP, FULC, AURA, and ATAI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/21/2025	Q1 2025	ATAI Atai Life Sciences	-$0.19	N/A	N/A	N/A	N/A	N/A
5/13/2025	Q1 2025	ADAP Adaptimmune Therapeutics	-$0.17	N/A	N/A	N/A	$6.55 million	N/A
5/12/2025	Q1 2025	FULC Fulcrum Therapeutics	-$0.29	N/A	N/A	N/A	N/A	N/A
5/1/2025	Q1 2025	FULC Fulcrum Therapeutics	-$0.29	-$0.28	+$0.01	-$0.28	N/A	N/A
3/24/2025	Q4 2024	ADAP Adaptimmune Therapeutics	-$0.17	-$0.26	-$0.09	-$0.29	$16.56 million	$3.22 million
3/24/2025	Q4 2024	AURA Aura Biosciences	-$0.43	-$0.52	-$0.09	-$0.52	N/A	N/A
3/17/2025	Q4 2024	ATAI Atai Life Sciences	-$0.14	-$0.24	-$0.10	-$0.24	$0.30 million	($0.01) million
2/25/2025	Q4 2024	FULC Fulcrum Therapeutics	-$0.28	-$0.31	-$0.03	-$0.31	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADAP Adaptimmune Therapeutics	N/A	N/A	N/A	N/A	N/A
ATAI Atai Life Sciences	N/A	N/A	N/A	N/A	N/A
AURA Aura Biosciences	N/A	N/A	N/A	N/A	N/A
FULC Fulcrum Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADAP Adaptimmune Therapeutics	0.62	3.85	3.82
ATAI Atai Life Sciences	0.14	5.81	5.81
AURA Aura Biosciences	N/A	12.47	12.47
FULC Fulcrum Therapeutics	N/A	18.44	18.44

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADAP Adaptimmune Therapeutics	31.37%
ATAI Atai Life Sciences	28.41%
AURA Aura Biosciences	96.75%
FULC Fulcrum Therapeutics	89.83%

Insider Ownership

Company	Insider Ownership
ADAP Adaptimmune Therapeutics	12.74%
ATAI Atai Life Sciences	31.20%
AURA Aura Biosciences	5.40%
FULC Fulcrum Therapeutics	4.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADAP Adaptimmune Therapeutics	490	257.23 million	224.05 million	Optionable
ATAI Atai Life Sciences	80	199.80 million	115.45 million	Optionable
AURA Aura Biosciences	50	50.23 million	47.25 million	Not Optionable
FULC Fulcrum Therapeutics	100	53.98 million	51.73 million	Optionable

ADAP, FULC, AURA, and ATAI Headlines

Recent News About These Companies

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 9 at 4:30 PM | globenewswire.com

Fulcrum Therapeutics (FULC) Projected to Post Earnings on Monday

May 7 at 8:12 AM | marketbeat.com

Fulcrum Therapeutics (NASDAQ:FULC) Announces Earnings Results, Beats Estimates By $0.01 EPS

May 5, 2025 | marketbeat.com

Boothbay Fund Management LLC Reduces Stake in Fulcrum Therapeutics, Inc. (NASDAQ:FULC)

May 5, 2025 | marketbeat.com

Susquehanna Fundamental Investments LLC Purchases Shares of 213,213 Fulcrum Therapeutics, Inc. (NASDAQ:FULC)

May 4, 2025 | marketbeat.com

Earnings call transcript: Fulcrum Therapeutics Q1 2025 reveals improved net loss

May 3, 2025 | uk.investing.com

Fulcrum Therapeutics, Inc. (FULC) Q1 2025 Earnings Call Transcript

May 2, 2025 | seekingalpha.com

Fulcrum therapeutics targets key data from PIONEER trial in Q3 2025

May 2, 2025 | msn.com

Q1 2025 Fulcrum Therapeutics Inc Earnings Call

May 2, 2025 | finance.yahoo.com

Fulcrum Therapeutics Inc (FULC) Q1 2025 Earnings Call Highlights: Strategic Cost Reductions and ...

May 2, 2025 | finance.yahoo.com

Why Fulcrum Therapeutics, Inc.’s (FULC) Stock Is Up 7.37%

May 2, 2025 | aaii.com

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2025

May 1, 2025 | globenewswire.com

2FULC : Uncovering Potential: Fulcrum Therapeutics's Earnings Preview

April 30, 2025 | benzinga.com

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Shares Acquired by Adage Capital Partners GP L.L.C.

April 30, 2025 | marketbeat.com

Fulcrum Therapeutics to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 8:00 a.m. ET

April 24, 2025 | globenewswire.com

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Average Recommendation of "Hold" from Brokerages

April 21, 2025 | marketbeat.com

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Sees Large Decrease in Short Interest

April 20, 2025 | marketbeat.com

Fulcrum repurposes failed GSK drug for rare disease

April 20, 2025 | pharmaphorum.com

Altium Capital Management LLC Buys Shares of 111,812 Fulcrum Therapeutics, Inc. (NASDAQ:FULC)

April 20, 2025 | marketbeat.com

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 11, 2025 | globenewswire.com

Fulcrum Metals inks deal to sell Tully Gold Project interest

April 9, 2025 | sharecast.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADAP, FULC, AURA, and ATAI Company Descriptions

Adaptimmune Therapeutics NASDAQ:ADAP

$0.29 -0.01 (-2.47%)

As of 05/9/2025 03:59 PM Eastern

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Atai Life Sciences NASDAQ:ATAI

$1.39 -0.01 (-0.71%)

As of 05/9/2025 04:00 PM Eastern

Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

Aura Biosciences NASDAQ:AURA

$5.23 -0.57 (-9.83%)

As of 05/9/2025 03:58 PM Eastern

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Fulcrum Therapeutics NASDAQ:FULC

$5.37 -0.04 (-0.74%)

As of 05/9/2025 04:00 PM Eastern

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time